Smart pills market seen topping $10 billion by 2030

The global smart pills market is projected to climb from $6.11 billion in 2025 to $10.13 billion by 2030, powered by chronic disease growth, remote monitoring demand and broader digital health adoption. North America led the market in 2025, while non-invasive diagnostics and rising healthcare spending are helping expand use cases.

Why it matters: - The smart pills market is moving from a niche digital-health tool toward a broader clinical workflow technology. - Growth is tied to medication adherence, remote monitoring and non-invasive diagnostics, all of which can lower friction for patients and providers. - The market’s projected climb to $10.13 billion by 2030 signals continued investment in connected health hardware and ingestible sensors.

What happened: - The Business Research Company published its Smart Pills Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report estimates the market will rise from $6.11 billion in 2025 to $6.75 billion in 2026. - The report projects the market will reach $10.13 billion by 2030. - The report says North America held the largest share of the global smart pills market in 2025. - Western Europe ranked as the second-largest regional market.

The details: - Smart pills are medication delivery devices with electronic sensors that transmit data to external devices such as patches or smartphones after ingestion. - The devices are designed to support prescribed drug regimens and help healthcare providers monitor adherence. - The report links recent growth to chronic disease prevalence, digital health initiatives, sophisticated ingestible sensors and broader use in clinical research. - Forecast growth is tied to personalized medicine, digital therapeutics, remote patient monitoring, smart drug delivery platforms and regulatory support for connected health technologies. - The report highlights sensor-enabled drug delivery systems, medication adherence solutions, mobile health integration, smart ingestible diagnostics and miniaturized electronics as key trends. - The report includes coverage of Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The full report is available here, and a free sample is available here.

Between the lines: - The market case is less about consumer wellness and more about healthcare systems trying to improve adherence, monitoring and outcomes. - Non-invasive procedures are becoming a stronger commercial driver because they can reduce recovery time and avoid surgical entry. - NHS England reported in March 2024 that more than 5,400 patients benefited from colon capsule endoscopy pill-cam pilots across 53 sites, underscoring clinical interest in swallowable diagnostics. - Rising healthcare spending supports adoption of technologies that can improve care efficiency and long-term disease management. - CMS reported in December 2024 that U.S. national health expenditures rose 7.5% to $4.9 trillion in 2023, equal to 17.6% of GDP. - CMS projects average annual health spending growth of 5.6% from 2023 to 2032, with the share of GDP spent on health rising from 17.3% in 2022 to 19.7% in 2032.

What's next: - Market growth is expected to continue as demand builds for personalized medicine, remote monitoring and connected drug-delivery tools. - Adoption will likely depend on regulatory clarity, reimbursement support and continued miniaturization of sensor technology. - The report’s 2026 research update suggests more attention on forecasting, regional hotspots and technology trends as the category matures.

The bottom line: - Smart pills are shifting from an emerging concept to a larger healthcare market with clear momentum, especially where non-invasive diagnostics and adherence monitoring overlap.